| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Protagenic Therapeutics, Inc.\new | Chief Financial Officer | PTIX Common stock Options | 100,000 | $174,000 | $1.74 | 25 Mar 2024 | Direct |
| Protagenic Therapeutics, Inc.\new | Chief Financial Officer | PTIX Common Stock | 45,815 | $37,110 | $0.8100 | 12 Oct 2023 | Direct |
| 8i Acquisition 2 Corp. | Exit | Ordinary Shares, no par value | 3,000 | 22 Nov 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PTIX | Protagenic Therapeutics, Inc.\new | 25 Mar 2024 | 1 | +$174,000 | 4 | Chief Financial Officer | 29 Mar 2024, 21:29 |
| PTIX | Protagenic Therapeutics, Inc.\new | 12 Oct 2023 | 1 | +$6,480 | 4 | Chief Financial Officer | 13 Oct 2023, 12:48 |
| EUDA | EUDA Health Holdings Ltd | 17 Nov 2022 | 0 | $0 | 4 | Exit | 25 Nov 2022, 15:05 |
| PTIX | Protagenic Therapeutics, Inc.\new | 17 May 2022 | 2 | +$22,090 | 4 | Chief Financial Officer | 18 May 2022, 17:11 |
| EUDA | 8i Acquisition 2 Corp. | 22 Nov 2021 | 0 | $0 | 3 | Director | 22 Nov 2021, 16:00 |
| PTIX | Protagenic Therapeutics, Inc.\new | 02 Jun 2021 | 2 | +$6,460 | 4 | Chief Financial Officer | 03 Jun 2021, 18:13 |
| PTIX | Protagenic Therapeutics, Inc.\new | 27 May 2021 | 1 | +$1,140 | 4 | Chief Financial Officer | 01 Jun 2021, 06:05 |
| PTIX | Protagenic Therapeutics, Inc.\new | 18 May 2021 | 2 | +$9,420 | 4 | Chief Financial Officer | 20 May 2021, 16:24 |